title: Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats.
abstract: Myo-inositol hexaphosphate (InsP6) is an abundant component of plant seeds. It is also found in significant levels in blood and mammalian tissues, but they are totally dependent on their dietary intake. In the present paper, we describe studies on the effect of InsP6 on a model of dystrophic calcification, which was chemically induced by subcutaneous injection of a 0.1% KMnO4 solution. Male Wistar rats were randomly divided into four groups for treatment over 31 days. A: animals consuming a purified diet in which InsP6 was absent but to which 1% of InsP6 (as sodium salt) was added. In this group, the InsP6 plasma levels (0.393 +/- 0.013 microM) were similar to those observed in rats consuming a standard diet. B: animals consuming only the purified diet in which InsP6 was absent. In this case the InsP6 plasma levels decreased (0.026 +/- 0.006 microM); C: animals consuming the same purified diet as group B but received daily subcutaneous injections of 50 microg kg(-1) etidronate during the last 14 days. In this case the InsP6 plasma levels were also very low (0.025 +/- 0.007 microM); D: animals consuming the same diet as group B but a 6% of carob germ (InsP6 rich product) was added. The InsP6 plasma levels (0.363 +/- 0.035 microM) were also similar to those observed in rats consuming a standard diet. After 21 days plaque formation was induced. Calcification plaques were allowed to proceed for 10 days, after which the plaque material present was excised, dried and weighed. It was found that the presence of myo-inositol hexaphosphate (phytate) in plasma at normal concentrations (0.3-0.4 microM) clearly inhibited the development of dystrophic calcifications in soft tissues. These results demonstrates that myo-inositol hexaphosphate acts as an inhibitor of calcium salt crystallization.
authors.affiliation: Laboratory of Renal Lithiasis Research, Institute of Health Sciences (IUNICS), University of Balearic Islands, Ctra. Valldemossa Km 7.5, 07071, Palma de Mallorca, Spain. fgrases@uib.es
authors.forename: F
authors.initials: F
authors.lastname: Grases
authors.forename: J
authors.initials: J
authors.lastname: Perelló
authors.forename: R M
authors.initials: RM
authors.lastname: Prieto
authors.forename: B M
authors.initials: BM
authors.lastname: Simonet
authors.forename: J J
authors.initials: JJ
authors.lastname: Torres
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002114:Calcinosis / Q000139:chemically induced / Q000517:prevention & control*; D004032:Diet; D004195:Disease Models, Animal; D012968:Etidronic Acid / Q000008:administration & dosage / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008297:Male; D010833:Phytic Acid / Q000008:administration & dosage / Q000494:pharmacology; D010865:Pilot Projects; D011196:Potassium Permanganate / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar
chemical_list: D011196:Potassium Permanganate; D010833:Phytic Acid; D012968:Etidronic Acid